Yes, Methotrexate Can Cause Liver Damage Over Time
Methotrexate, a drug used for rheumatoid arthritis, psoriasis, and cancer, carries a known risk of liver toxicity with long-term use. It can lead to elevated liver enzymes, fatty liver, fibrosis, cirrhosis, or outright liver failure in some patients. This risk increases with cumulative dosing, often after months or years of treatment.[1][2]
How Does Methotrexate Damage the Liver?
The drug interferes with folate metabolism, causing hepatocyte injury and inflammation. Low doses (e.g., 7.5-25 mg weekly for autoimmune conditions) are less risky than high-dose chemotherapy regimens, but repeated exposure builds up damage. Autopsy studies show up to 90% of long-term users have some liver changes, though most are mild.[3][4]
Who Gets Liver Damage and How Often?
Risk factors include higher cumulative doses (>1.5-4 grams total), alcohol use, obesity, diabetes, or pre-existing liver disease. About 5-20% of rheumatoid arthritis patients on low-dose methotrexate develop significant fibrosis after 2-5 years. Regular monitoring catches issues early in most cases.[1][5]
How Do Doctors Monitor for This?
Guidelines from the American College of Rheumatology recommend liver function tests (ALT, AST) every 1-3 months initially, then less often if stable. Some use FibroScan or biopsies for high-risk patients. Dose adjustments or stops prevent progression.[2][6]
What Happens If Liver Damage Occurs?
Mild elevations often reverse after pausing the drug. Advanced fibrosis or cirrhosis may not fully heal, leading to permanent issues or transplant needs in rare cases (less than 1%). Patients report fatigue, jaundice, or ascites as symptoms.[4][7]
Can You Avoid or Reduce the Risk?
Folic acid supplements (1-5 mg daily) cut toxicity by 70-80% without reducing efficacy. Limit alcohol, maintain healthy weight, and avoid other hepatotoxins. Switching to alternatives like leflunomide or biologics is common if damage appears.[1][3]
Alternatives If Liver Risk Is a Concern
For rheumatoid arthritis, options include hydroxychloroquine (lower liver risk), sulfasalazine, or TNF inhibitors like etanercept. In psoriasis, apremilast or biologics like ixekizumab avoid methotrexate's profile.[5][8]
[1]: American College of Rheumatology Guidelines on Methotrexate
[2]: Drugs.com - Methotrexate Side Effects
[3]: NEJM Review on Methotrexate Hepatotoxicity
[4]: PubMed - Long-term Liver Effects of Methotrexate
[5]: Arthritis Foundation - Methotrexate Safety
[6]: FDA Label - Methotrexate
[7]: LiverTox - Methotrexate
[8]: UpToDate - DMARD Alternatives